Hodgkin Lymphoma: Comments on ESMO Clinical Practice Guidelines

Hodgkin Lymphoma: Comments on ESMO Clinical Practice Guidelines - European Hematology Association

HL is a highly curable disease by current treatment modalities with a reported 5-year survival of 90% in 2015 in the United States.3 However, if we consider that in HL survivorship starts with initial treatment selection, the availability of recommendations prepared by experts in the field represent a relevant support for decision making in the daily practice.

The ESMO for HL guidelines were based on results of studies whose results were available in 2018 and provided robust recommendations regarding treatment strategies designed on PET based staging and early response assessment.4 In the past 2 years, some new data emerged which we will discuss in this editorial.


Read full Guideline